Ancient Chinese Herb Compound Halofuginone Could Be Detoxified Into Safer Cancer Drug

For more than two thousand years, physicians in traditional Chinese medicine have brewed a tea from the roots and leaves of Dichroa febrifuga, a flowering shrub known as Chang Shan, to treat fevers caused by malaria. Modern chemistry eventually isolated the active principle, an alkaloid called febrifugine, and pharmaceutical researchers later engineered a halogenated derivative known as halofuginone. A comprehensive new review published in Discover Biotechnology by Ghulam Jilany Khan, Aqsa Maimoona Malik, and Rabia Nasrullah now surveys seven decades of research on this remarkable molecule, arguing that its extraordinary chemical versatility could be harnessed for cancer therapy if only its troubling toxicity could be engineered away through a change of salt.

Halofuginone first entered industrial use as a veterinary anticoccidial agent, sold under the trade name Stenorol to protect poultry from Eimeria parasites, and it received US Food and Drug Administration certification in the early 1980s. Its IUPAC name, 7-bromo-6-chloro-3-[3-[(2S,3R)-3-hydroxy-2-piperidinyl]-2-oxopropyl]-4-quinazolinone, hints at its architecture: a quinazolinone ring decorated with bromine and chlorine atoms, joined through a ketone linker to a hydroxylated piperidine ring. Each of these three structural modules has been systematically modified in the search for better analogues, and the review meticulously catalogs how substitutions at the 5th, 6th, 7th, and 8th positions of the quinazolinone ring, alterations of the piperidine nitrogen, and replacements of the ketone linker all shape biological activity.

At the molecular level, halofuginone’s most celebrated target is prolyl-tRNA synthetase, the enzyme that charges transfer RNA molecules with the amino acid proline during protein synthesis. Crystallographic work showed that the drug binds this enzyme in an ATP-dependent manner, simultaneously mimicking the bound amino acid and the 3′-terminal region of tRNA. Inhibition triggers an intracellular buildup of uncharged tRNA and activates what biologists call the amino acid starvation response, a stress pathway that in immune cells suppresses the differentiation of inflammatory Th17 lymphocytes. This unusual mechanism, unique among known aminoacyl-tRNA synthetase inhibitors, explains the drug’s simultaneous antimalarial, antifibrotic, anti-inflammatory, and anticancer effects, since proliferating parasites, fibroblasts, and tumor cells all depend on proline-rich protein production.

The anticancer evidence assembled in the review is strikingly broad. In gastric cancer models, halofuginone blocked STAT3 phosphorylation and vascular endothelial growth factor signaling, shrinking tumors and disrupting contacts between malignant cells and cancer-associated fibroblasts. In colorectal cancer, it suppressed the PI3K-Akt-mTORC1 axis, curtailed glucose-6-phosphate dehydrogenase activity, depleted NADPH, and drove cancer cells into G0/G1 arrest followed by caspase-mediated apoptosis. In breast cancer, the drug suppressed both STAT3 and NRF2, two transcription factors whose interplay promotes survival, epithelial-mesenchymal transition, and metastasis. Lung cancer cells exposed to halofuginone underwent G1/S arrest and apoptosis through a rising Bax-to-Bcl-2 ratio and cleavage of caspase-3 and PARP, while hepatocellular carcinoma cells responded with selective inhibition of CDK2, CDK4/6, and CDK1 alongside activation of the caspase cascade.

Beyond oncology, the review documents an impressive therapeutic spectrum. As an antifibrotic agent, halofuginone blocks transforming growth factor beta signaling at the level of Smad3 phosphorylation, reduces collagen type I expression, and has shown benefit in models of pulmonary fibrosis, hepatic and pancreatic fibrosis, Duchenne muscular dystrophy, chronic graft-versus-host disease, and scleroderma. As an antiprotozoal, its lactate salt prevents cryptosporidiosis in calves and lambs and its hydrobromide salt controls coccidiosis in poultry by disrupting schizont development in the parasite gut. The drug also prevents extracellular matrix deposition in diabetic nephropathy by suppressing TGF-beta receptor expression, and it reverses pulmonary hypertension by activating potassium channels, blocking calcium influx, and inhibiting the PI3K-Akt-mTOR pathway in pulmonary artery smooth muscle. Trials have even evaluated it against non-hospitalized COVID-19 in the phase II HALOS study.

Yet the molecule’s clinical progress has stalled at phase II, and the review identifies the reasons with unusual candor. Halofuginone is neurotoxic and gastrotoxic, and its available formulations, the hydrobromide and lactate salts, carry gastrointestinal and hepatic liabilities. In the first-in-human phase I trial of patients with advanced solid tumors, the maximum tolerated dose was 3.5 milligrams per day, with nausea, vomiting, and lethargy as dose-limiting toxicities, and the recommended chronic dose of 0.5 milligrams daily requires antiemetic support. The authors point to the toxicology of the bromide counterion itself, which has long been associated with gastric irritation and central nervous system effects including confusion and hallucinations, as a contributor to these problems.

It is here that the review makes its most consequential proposal: reformulate halofuginone as a hydrochloride salt. The authors marshal a century of pharmaceutical evidence, noting that roughly seventy percent of marketed drugs exist as salts and that hydrochlorides dominate the halide family, accounting for the large majority of the approximately six hundred novel drug salts approved between 1939 and 2022. From ciprofloxacin and moxifloxacin to donepezil, trazodone, raloxifene, and pexidartinib, hydrochloride formation has repeatedly improved solubility, dissolution rate, chemical stability, manufacturability, and bioavailability of weakly basic drugs with ionizable nitrogen atoms, exactly the profile halofuginone presents.

Supporting this proposal, the team ran computational predictions on the proposed hydrochloride using Molinspiration and ADMET Lab 2.0 software. The virtual compound scored favorably across Lipinski’s rule of five, achieved a drug-likeness quantifier of 0.857, showed moderate aqueous solubility with a logS of -1.933, low synthetic accessibility, acceptable plasma protein binding of 49.7 percent, and good blood-brain barrier penetration, while posing low CYP450 inhibition risk. The predictions were not uniformly rosy: limited intestinal absorption and strong P-glycoprotein substrate behavior may constrain oral bioavailability, and a relatively short predicted half-life suggests formulation work remains. The authors also flag well-known pitfalls of hydrochloride salts, including common-ion precipitation in the acidic stomach environment and hygroscopicity under humid conditions, which demand careful stoichiometric control and process validation.

What emerges from this synthesis is a portrait of a molecule caught between promise and peril. Halofuginone inhibits a single, mechanistically elegant enzyme and thereby touches inflammation, fibrosis, metabolism, parasitology, and malignancy at once, a breadth few synthetic drugs can claim. Its structure-activity relationship is now well mapped: bromine and chlorine at the 6 and 7 positions of the quinazolinone ring confer a sixty-four-fold potency gain against prolyl-tRNA synthetase, removal of the piperidine hydroxyl enhances antibacterial activity, and disruption of the ketone linker or the ring nitrogen positions abolishes activity. The stereochemical configuration matters profoundly, with the trans-(2R,3S) enantiomer proving the most potent. With such detailed chemical understanding in hand, salt selection becomes a rational lever rather than an empirical guess.

The review’s authors close with a call to the medicinal chemistry community: explore novel halofuginone derivatives with alternative halogen salts, particularly the hydrochloride, to enhance pharmacokinetics and pharmacodynamics while minimizing dose-limiting toxicities, and to pursue extended-release and nanoformulation strategies that have already shown reduced systemic toxicity in preclinical models. If that reformulation succeeds, a compound derived from an ancient fever remedy, long confined to the poultry feed industry, could finally complete its journey into human oncology wards, vindicating the idea that sometimes the fastest route to a better drug is not a new molecule but a new form of an old one.

Subject of Research: The chemical versatility, toxicity profile, and salt-based detoxification of the plant-derived drug halofuginone for future pharmacotherapeutic applications.

Article Title: Chemical versatility of Halofuginone and its detoxification for future pharmacotherapeutic applications

Article References: Khan, G. J., Malik, A. M., & Nasrullah, R. (2025). Chemical versatility of Halofuginone and its detoxification for future pharmacotherapeutic applications. Discover Biotechnology, 2(1), Article 32. https://doi.org/10.1007/s44340-025-00039-6

Image Credits: AI Generated

DOI: 10.1007/s44340-025-00039-6

Keywords: halofuginone, febrifugine, prolyl-tRNA synthetase, anticancer drug discovery, pharmaceutical salts, natural products, fibrosis, halofuginone hydrochloride, drug toxicity, structure-activity relationship, Dichroa febrifuga, clinical trials